TD Cowen Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $10
TD Cowen analyst Nicholas Lorusso maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $7 to $10.
Read original at benzingaStocks · News reference
8-K filing — IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Filed: 2026-08-06 AccNo: 0001104659-26-091619 Size: 309 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 6, 2026, 11:05 AM
- Checked
- Aug 6, 2026, 11:05 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Iovance Biotherapeutics Stock Is Trending Friday: What's Going On?
Shares of Iovance Biotherapeutics are trending Friday morning after a momentum surge pushed the biotech stock to a new 52-week high.
Read original at benzingaIovance Biotherapeutics shares are trading higher after UBS maintained its Neutral rating on the stock and raised its price target from $4 to $7.
Read original at benzingaWhy Iovance Biotherapeutics Stock Hit 52-Week High
Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amtagvi sales and analyst price target hikes.
Read original at benzinga